National Healthcare Corp (NHC) · Nov 6, 2026 · Earnings
In line — No published consensus; adj. EPS $1.76 vs $1.58 prior year
National HealthCare earnings show acquisition-driven revenue growth and higher adjusted EPS, offset by a sharp GAAP profit decline.
National HealthCare is expanding its senior-care operating platform while shifting formerly leased facilities into owned real estate; the July purchase from National Health Investors was already announced and completed before this quarter, so the transaction itself is not new.
The operating story improved, but mainly because of acquired assets. Third-quarter revenue rose 6.6%, while adjusted net income increased 13.8% and adjusted diluted EPS rose to $1.76 from $1.58. The filing says the earnings increase was primarily driven by the June and July acquisitions, including 35 NHI real-estate assets representing 4,825 licensed beds. 〔0〕
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Net operating revenues (Financial Data) | $408.0M (+6.6%) | $382.7M | |
| Adjusted diluted EPS (Financial Data) | $1.76 (+11.4%) | $1.58 | |
| GAAP diluted EPS (Financial Data) | $0.85 (-66.0%) | $2.50 | |
| Adjusted net income (Financial Data) | $28.2M (+13.8%) | $24.7M |
GAAP quality is the clear complication. Reported net income fell to $13.6 million from $39.2 million, and GAAP diluted EPS dropped to $0.85 from $2.50, even as the company emphasized adjusted results. Because the filing does not provide a published consensus or a detailed reconciliation of every adjustment in the release, the cleanest read is not a substantiated beat or miss: underlying earnings improved, but the headline GAAP result deteriorated sharply.
Bottom line: The quarter modestly advances NHC’s acquisition-led growth story, but it is not a clean win: better adjusted operating earnings came alongside a much weaker GAAP result. The acquisitions are contributing, yet the quality and durability of reported profit remain the main unresolved issue.
Q4 earnings report, expected February 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!